Key Financials | KlickAnalytics

Global Standardized Financials

748.87 -18.98 (-2.47%) 04/10/2026

Regeneron Pharmaceuticals, Inc. (REGN)

Income Statement

(Values in Thousands)

	Q4 2025 (Dec 31, 2025)	Q3 2025 (Sep 30, 2025)	Q2 2025 (Jun 30, 2025)	Q1 2025 (Mar 31, 2025)	Q4 2024 (Dec 31, 2024)	Q3 2024 (Sep 30, 2024)	Q2 2024 (Jun 30, 2024)	Q1 2024 (Mar 31, 2024)	Q4 2023 (Dec 31, 2023)	Q3 2023 (Sep 30, 2023)	Q2 2023 (Jun 30, 2023)	Q1 2023 (Mar 31, 2023)	Q4 2022 (Dec 31, 2022)	Q3 2022 (Sep 30, 2022)	Q2 2022 (Jun 30, 2022)	Q1 2022 (Mar 31, 2022)	Q4 2021 (Dec 31, 2021)	Q3 2021 (Sep 30, 2021)	Q2 2021 (Jun 30, 2021)	Q1 2021 (Mar 31, 2021)	Q4 2020 (Dec 31, 2020)	Q3 2020 (Sep 30, 2020)	Q2 2020 (Jun 30, 2020)	Q1 2020 (Mar 31, 2020)	Q4 2019 (Dec 31, 2019)	Q3 2019 (Sep 30, 2019)	Q2 2019 (Jun 30, 2019)	Q1 2019 (Mar 31, 2019)	Q4 2018 (Dec 31, 2018)	Q3 2018 (Sep 30, 2018)	Q2 2018 (Jun 30, 2018)	Q1 2018 (Mar 31, 2018)	Q4 2017 (Dec 31, 2017)	Q3 2017 (Sep 30, 2017)	Q2 2017 (Jun 30, 2017)	Q1 2017 (Mar 31, 2017)	Q4 2016 (Dec 31, 2016)	Q3 2016 (Sep 30, 2016)	Q2 2016 (Jun 30, 2016)	Q1 2016 (Mar 31, 2016)
Net Income	844,600	1,460,000	1,391,600	808,700	917,700	1,340,600	1,432,300	722,000
Revenue	3,884,300	3,754,300	3,675,600	3,028,700	3,789,200	3,720,700	3,547,100	3,145,000
Cost Of Revenue	584,600	521,600	530,200	464,300	565,400	491,100	480,200	433,800
Gross Profit	3,299,700	3,232,700	3,145,400	2,564,400	3,223,800	3,229,600	3,066,900	2,711,200
Operating Expenses	2,419,800	2,205,900	2,065,900	1,972,700	2,233,600	2,050,100	1,997,300	1,959,800
Selling General and Administrative Expenses	775,000	657,800	634,200	633,000	792,200	714,400	758,800	689,000
Research and Development Expenses	1,626,100	1,558,100	1,431,700	1,339,700	1,425,900	1,327,700	1,223,900	1,255,500
Other Expenses	18,700	-10,000			15,500	8,000	14,600	15,300
Cost And Expenses	3,004,400	2,727,500	2,596,100	2,437,000	2,799,000	2,541,200	2,477,500	2,393,600
Operating Income	879,900	1,026,800	1,079,500	591,700	990,200	1,179,500	1,069,600	751,400
Interest Income	193,300	175,100	174,800	173,500	183,100	187,400	179,400	161,500
Income Tax Expense	199,100	303,300	127,100	96,300	40,400	152,400	195,800	-21,300
Income Before Tax	1,043,700	1,763,300	1,518,700	905,000	958,100	1,493,000	1,628,100	700,700
Earning Per Share Basic	8.21	14.09	13.24	7.58	8.53	12.40	13.25	6.70
Earning Per Share Diluted	7.86	13.62	12.81	7.27	8.06	11.54	12.41	6.27
weighted Average Shares Outstanding	102,900	103,620	105,100	106,700	107,900	108,100	108,100	107,800
weighted Average Shares Outstanding (Diluted)	107,500	107,200	108,600	111,200	113,800	116,200	115,400	115,100
Gross Margin	0.85	0.86	0.86	0.85	0.85	0.87	0.86	0.86
EBIT Margin	0.31	0.51	0.45	0.34	0.29	0.44	0.50	0.26
Profit Margin	0.22	0.39	0.38	0.27	0.24	0.36	0.40	0.23
EBITDA	1,200,900	1,919,300	1,657,400	1,040,600	1,095,000	1,628,500	1,763,600	830,900
Earning Before Tax Margin	0.27	0.47	0.41	0.30	0.25	0.40	0.46	0.22